Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Insperity, Inc. (NSP) SEC Filings & Earnings Calls

EquiReason read 11 Insperity, Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-07-30 — Insperity reported Q2 2026 results: revenue +2%, adjusted EBITDA +13%, but gross profit -3% and WSEEs -1% YoY..

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

NSPInsperity, Inc.Follow NSP — free
Staffing & Employment Services · Industrials
—
Price chart with a free account
Market cap
2.1B
P/E TTM
—
Dividend yield
4.4%
52-week
—
Next earnings
29 Oct, in 5 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

30 Jul 202610-QInsperity reported Q2 2026 results: revenue +2%, adjusted EBITDA +13%, but gross profit -3% and WSEEs -1% YoY.earningsopen

Figures in the filing · each found in the filing text

Revenue · Q2-2026$1.69B+2% y/y
Gross Profit · Q2-2026$217M-3% y/y
Net Income · Q2-2026$4M+180% y/y
Adjusted EBITDA · Q2-2026$36M+13% y/y
Adjusted EPS · Q2-2026$0.34+31% y/y
Diluted EPS · Q2-2026$0.10+171% y/y
Revenue per WSEE per month · Q2-2026$1838.00+3% y/y
Gross Profit per WSEE per month · Q2-2026$237.00-1% y/y

Risks flagged

Healthcare cost inflation

“The cost of group health insurance and related employee benefits increased $25 per WSEE per month and increased 5.2% on a cost per covered employee basis in Q2 2026 as compared to Q2 2025.” · word for word

Workers' compensation cost spike

“Workers' compensation costs increased 35%, or $8 per WSEE per month, in Q2 2026 compared to Q2 2025 and has been impacted, in part, by elevated health care cost trends.” · word for word

Client attrition from pricing actions

“The number of WSEEs paid from new client sales and client retention decreased due in part to our margin recovery efforts” · word for word
Read the original on SEC EDGAR ↗
29 Jul 20268-K · 2.02Average paid WSEEs 305,764 (-1% y/y); Revenue $1.70B (+2% y/y); Gross profit $217M (-3% y/y); Guidance: Full-year 2026 average WSEEs guided to 305,000-307,000 (YoY -1.0% to -1.6%); adjusted EPS $1.88-$2.43; adjusted EBITDA $185M-$225M.earningsopen

Figures in the filing · each found in the filing text

Average paid WSEEs · Q2-2026305,764-1% y/y
Revenue · Q2-2026$1.70B+2% y/y
Gross profit · Q2-2026$217M-3% y/y
Net income · Q2-2026$4M+180% y/y
Adjusted EBITDA · Q2-2026$36M+13% y/y
Diluted EPS · Q2-2026$0.10+171% y/y
Adjusted EPS · Q2-2026$0.34+31% y/y
Gross profit per WSEE · Q2-2026$237.00-1% y/y
Adjusted cash · Q2-2026$95M

Guidance

Full-year 2026 average WSEEs guided to 305,000-307,000 (YoY -1.0% to -1.6%); adjusted EPS $1.88-$2.43; adjusted EBITDA $185M-$225M.

Guidance cut reflects continued decline in worksite employees, but margin recovery plan is on track with adjusted EBITDA expected to grow 41%-72% in 2026.

Risks flagged

Declining worksite employee count signals weak demand for HR outsourcing services, potentially due to macroeconomic headwinds or competitive pressures.

“Average paid WSEEs down 1% YoY in Q2 and full-year guidance implies further decline.”

Benefits cost inflation pressuring gross margins; benefits costs per covered employee up 5% YoY.

“Benefits costs per covered employee increased 5% over Q2 2025.” · word for word

High debt levels: $420 million outstanding under credit facility at June 30, 2026, with $50 million borrowed in Q2 for working capital.

“Outstanding borrowings of $420 million under credit facility at June 30, 2026.”
Read the original on SEC EDGAR ↗
20 May 20268-K · 5.02, 5.07Reported the departure of a director or principal officer (CEO/CFO change); submitted matters to a vote of security holdersSEC ↗
1 May 202610-QAverage WSEEs paid 303,049 (-1% y/y); Revenue $1.90B (+2% y/y); Gross profit $302M (-3% y/y)open

Figures in the filing · each found in the filing text

Average WSEEs paid · Q1-2026303,049-1% y/y
Revenue · Q1-2026$1.90B+2% y/y
Gross profit · Q1-2026$302M-3% y/y
Net income · Q1-2026$33M-35% y/y
Adjusted EBITDA · Q1-2026$103M+1% y/y
Adjusted EPS · Q1-2026$1.31-17% y/y
Gross profit per WSEE per month · Q1-2026$332.00-2% y/y
Middle market WSEEs as % of total · Middle Market · Q1-202629.0%

Risks flagged

Healthcare cost inflation

“The cost of group health insurance and related employee benefits increased $28 per WSEE per month and increased 5.2% on a cost per covered employee basis in Q1 2026 as compared to Q1 2025.” · word for word

Workers' compensation cost increase

“Workers’ compensation costs increased 30%, or $7 per WSEE per month, in Q1 2026 compared to Q1 2025.” · word for word

Client attrition from margin recovery

“Average number of WSEEs paid per month decreased 1%, which was partially impacted by our margin recovery efforts.” · word for word
Read the original on SEC EDGAR ↗
30 Apr 20268-K · 2.02Insperity Q1 2026 earnings: revenue +2% to $1.9B, net income $33M, adjusted EBITDA $103M, diluted EPS $0.88, adjusted EPS $1.31. Average WSEEs -1% to 303,049. Guidance updated: Q2 2026 adjusted EPS $0.02-$0.50, FY2026 adjusted EPS $1.60-$2.earningsopen

Figures in the filing · each found in the filing text

Average WSEEs paid · Q1-2026303,049-1% y/y
Revenue · Q1-2026$1.90B+2% y/y
Net income · Q1-2026$33M
Adjusted EBITDA · Q1-2026$103M
Diluted EPS · Q1-2026$0.88
Adjusted EPS · Q1-2026$1.31
Gross profit · Q1-2026$302M-3% y/y
Operating expenses · Q1-2026$240M-1% y/y
Capital expenditures · Q1-2026$6M
Adjusted cash · 2026-03-31$36M

Guidance

Q2 2026: average WSEEs 302,500-304,500 (y/y -2.1% to -1.5%), adjusted EPS $0.02-$0.50 (y/y -92% to +92%), adjusted EBITDA $18M-$46M (y/y -44% to +44%). FY2026: average WSEEs 303,000-307,000 (y/y -2.3% to -1.0%), adjusted EPS $1.60-$2.60 (y/y +55% to +152%), adjusted EBITDA $170M-$230M (y/y +30% to +76%).

Guidance reflects continued WSEE decline but significant margin recovery; adjusted EPS and EBITDA expected to improve strongly in FY2026.

Risks flagged

Margin pressure from benefits cost inflation; benefits cost per covered employee +5%.

“Benefits costs per covered employee increased 5% over Q1 2025.” · word for word

Restructuring charges of $9 million related to workforce realignment.

“Operating expenses included $9 million in restructuring charges primarily related to severance.”

Outstanding borrowings of $370 million under credit facility.

“Outstanding borrowings of $370 million under our credit facility.” · word for word
Read the original on SEC EDGAR ↗
14 Apr 2026DEF 14AProxy statement disclosing executive compensation, pay-for-performance metrics, and governance practices for 2025.open

Figures in the filing · each found in the filing text

Adjusted EBITDA · FY2025$131M-52% y/y
Average Number of Worksite Employees Paid (WSEEs) · FY20250.9%
Regular Annual Dividend per Share · FY2025$2.400% y/y
Net Income · FY2025$-7M-108% y/y

Risks flagged

Workday Partnership Execution Risk

“Most of the investment associated with these development efforts were reflected as expenses, resulting in adjusted EBITDA of $131 million, which is lower compared to the prior year.” · word for word

Insider Pledge Risk

“Mr. Sarvadi had 250,000 shares of our common stock pledged, which represented approximately 17.0% of the shares of our common stock Mr. Sarvadi beneficially owned.” · word for word
Read the original on SEC EDGAR ↗
11 Feb 202610-KAverage WSEEs paid 310,089 (+1% y/y); Revenue $6.81B (+4% y/y); Gross Profit $900M (-14% y/y)open

Figures in the filing · each found in the filing text

Average WSEEs paid · PEO HR Solutions · FY2025310,089+1% y/y
Revenue · FY2025$6.81B+4% y/y
Gross Profit · FY2025$900M-14% y/y
Net Income (Loss) · FY2025$-7M-108% y/y
Adjusted EBITDA · FY2025$131M-51% y/y
Adjusted Net Income · FY2025$39M-71% y/y
Diluted EPS · FY2025$-0.19-108% y/y
Adjusted EPS · FY2025$1.03-71% y/y
Client Retention · FY202583.0%
Benefits Cost per Covered Employee · FY20259.2%

Risks flagged

Healthcare Cost Inflation

“The cost of group health insurance and related employee benefits increased $61 per WSEE per month, or 9.2% on a cost per covered employee basis.” · word for word

Insufficient Pricing Power

“Gross profit per WSEE paid per month reflected, in part, a 3% pricing increase offset by a 6% increase in direct costs per WSEE.” · word for word

Profitability Deterioration

“Net income (loss) ... decreased 108% to $(7) million. Adjusted EBITDA decreased 51% to $131 million.”

Liquidity Tightening

“At December 31, 2025, we had working capital of $102 million compared to $155 million at December 31, 2024.” · word for word
Read the original on SEC EDGAR ↗
10 Feb 20268-K · 2.02, 2.05Revenues $1.70B (+3% y/y); Average Paid WSEEs 312,377 (+1% y/y); Gross Profit $172M (-21% y/y); Guidance: Q1 2026 adjusted EPS $1.03-1.50; FY2026 adjusted EPS $1.69-2.72; adjusted EBITDA $170-230Mearningsopen

Figures in the filing · each found in the filing text

Revenues · Q4-2025$1.70B+3% y/y
Average Paid WSEEs · Q4-2025312,377+1% y/y
Gross Profit · Q4-2025$172M-21% y/y
Net Loss · Q4-2025$-33M
Diluted EPS · Q4-2025$-0.88
Adjusted EBITDA · Q4-2025$-13M
Adjusted EPS · Q4-2025$-0.60
Average Paid WSEEs (FY) · FY2025310,089+1% y/y
Revenues (FY) · FY2025$6.80B+4% y/y
Gross Profit (FY) · FY2025$900M-14% y/y

Guidance

Q1 2026 adjusted EPS $1.03-1.50; FY2026 adjusted EPS $1.69-2.72; adjusted EBITDA $170-230M

Guidance implies significant recovery in profitability from 2025 levels, but Q1 still weak.

Risks flagged

Elevated benefits costs (inpatient, outpatient, pharmacy, large claims) pressuring gross profit.

“elevated benefits costs were driven by inpatient, outpatient, and pharmacy trends, as well as frequency of large claim activity” · word for word

Restructuring plan with $9M charge; 4% reduction in non-sales positions.

“internal reorganization; elimination of approximately 4% of our non-sales positions; one-time charges of approximately $9 million”
Read the original on SEC EDGAR ↗
16 Dec 20258-K · 1.01, 2.03Entered a material definitive agreement (acquisition, partnership, or major contract); took on a material direct financial obligation, increasing leverageopen

Risks flagged

Higher leverage covenant may indicate increased risk appetite or operational challenges

“Maximum leverage ratio increased from 3.00x to 3.75x.”
Read the original on SEC EDGAR ↗
4 Nov 202510-QInsperity reported a sharp decline in profitability with net income swinging to a loss of $20M from a profit of $3M, driven by healthcare cost inflation.earningsopen

Figures in the filing · each found in the filing text

Average WSEEs paid · Q3-2025312,842+1% y/y
Revenues · Q3-2025$1.62B+4% y/y
Gross profit · Q3-2025$195M-15% y/y
Net income (loss) · Q3-2025$-20M-767% y/y
Adjusted EBITDA · Q3-2025$10M-74% y/y
Diluted EPS · Q3-2025$-0.53-857% y/y
Adjusted EPS · Q3-2025$-0.20-151% y/y
Gross profit per WSEE per month · Q3-2025$208.00-16% y/y
Revenues per WSEE per month · Q3-2025$1729.00+3% y/y
Operating cash flow · 9M-2025$-533M

Risks flagged

Healthcare cost inflation

“The cost of group health insurance and related employee benefits increased $60 per WSEE per month and increased 9.1% on a cost per covered employee basis driven by elevated inpatient, outpatient and pharmacy trends and frequency of large claim activity in Q3 2025 as compared to Q3 2024.” · word for word

Workers' compensation cost increase

“Workers' compensation costs increased 15%, or $3 per WSEE per month, in Q3 2025 compared to Q3 2024.” · word for word
Read the original on SEC EDGAR ↗
3 Nov 20258-K · 1.01, 2.02Revenue $1.60B (+4% y/y); Net loss $-20M; Adjusted EBITDA $10M; Guidance: Q4 adjusted EPS $(0.79)-$(0.16); full year adjusted EPS $0.84-$1.47open

Figures in the filing · each found in the filing text

Revenue · Q3-2025$1.60B+4% y/y
Net loss · Q3-2025$-20M
Adjusted EBITDA · Q3-2025$10M
Diluted EPS · Q3-2025$-0.53
Average paid WSEEs · Q3-2025312,842+1% y/y
Gross profit · Q3-2025$195M-15% y/y
Operating expenses · Q3-2025$220M-4% y/y
Share repurchases · First nine month$19M

Guidance

Q4 adjusted EPS $(0.79)-$(0.16); full year adjusted EPS $0.84-$1.47

Significant guidance cut due to healthcare cost pressure; new UHC contract expected to improve 2026 outlook.

Risks flagged

Elevated healthcare costs driven by inpatient, outpatient, and pharmacy trends; large claim frequency.

“Higher Q3 2025 healthcare costs were driven by elevated inpatient, outpatient and pharmacy trends and frequency of large claim activity.” · word for word

Q4 guidance implies significant year-over-year decline in profitability.

“Adjusted EPS $(0.79) — $(0.16)... Year-over-year decrease (77)% — (59)%” · word for word
Read the original on SEC EDGAR ↗

Insperity, Inc. — questions

What did Insperity, Inc. file recently?
11 SEC filings in the last 12 months. Latest: 10-Q on 2026-07-30 — Insperity reported Q2 2026 results: revenue +2%, adjusted EBITDA +13%, but gross profit -3% and WSEEs -1% YoY.

Every figure on this page comes from Insperity, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.